MIMRYLO Patient Support

We're Here2Assist® your patients

MIMRYLO Patient Support Program is a comprehensive patient support program that includes:

ACCESS SUPPORT

MIMRYLO Patient Support case managers can work with your patients’ insurance companies to conduct benefits verifications*, create a summary of coverage options for each enrolled patient, and send status updates and reminders via text message.^†

FINANCIAL ASSISTANCE

MIMRYLO Patient Support can help identify financial assistance programs that may be able to help your patients with the cost of their MIMRYLO treatment.

NURSING SUPPORT SERVICES

Supplemental nursing support services are available so your patients can ask questions and learn self-injection techniques after MIMRYLO has been prescribed.

HELPFUL RESOURCES

MIMRYLO Patient Support case managers are here to address your patients’ day-to-day treatment questions and provide resources and information about additional support.

*Verification of benefits is not a guarantee of payment and does not take the place of written policy information. Healthcare providers should carry out their own benefits investigation, as necessary.

^†Patients will need to enroll in the texting program to receive text messages.

Looking for more information? Let’s talk.
Call us at 1-844-817-6468, Option 2. We’re available Monday-Friday, 8AM-8PM ET.
To learn more about MIMRYLO Patient Support or to enroll in the program, visit www.Here2Assist.com/hcp.

All individuals in images are actor portrayals.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

New or Worsening Thrombocytosis: MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Injection-Site Reactions: Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Embryo-Fetal Toxicity: Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.

Females and Males of Reproductive Potential

Pregnancy Testing: Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.
Contraception: Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see MIMRYLO (rusfertide) full Prescribing Information.

MIMRYLO Patient Support

We're Here2Assist® your patients

IMPORTANT SAFETY INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

USE IN SPECIFIC POPULATIONS

INDICATION